Table 2 Outcomes and performance of risk scores and ProADM overall and in CAP and non-CAP-LRTI
Parameters | All patients (n = 1359) | CAP (n = 925) | Non-CAP (n = 379) | P* |
|---|---|---|---|---|
30 days outcomes | ||||
Outpatient treatment, no (%) | 142 (10%) | 81 (9%) | 61 (16%) | <0.001 |
Length of hospital stay, median (IQR) | 8 (4-12) | 8 (5-12) | 7 (3-11) | <0.001 |
All cause mortality, no (%) | 67 (4.9%) | 50 (5.4%) | 10 (2.6%) | 0.03 |
ICU admission, no (%) | 103 (7.6%) | 83 (9.0%) | 15 (4.0%) | 0.002 |
Empyema, no (%) | 31 (2.4%) | 31 (3.3%) | 0 | <0.001 |
Any adverse events, no (%) | 170 (12.2%) | 134 (14.5%) | 24 (6.3%) | <0.001 |
CURB65 score | ||||
CURB65 points, median (IQR) | 2 (1-2) | 2 (1-2) | 1 (1-2) | 0.002 |
CURB65 risk classes | 0.001 | |||
CURB65 0-1, no (%) | 659 (48.5%) | 427 (46.2%) | 211 (55.7%) | |
CURB65 2, no (%) | 434 (31.9%) | 296 (32.0%) | 114 (30.1%) | |
CURB65 3-5, no (%) | 266 (19.6%) | 202 (21.8%) | 54 (14.2%) | |
AUC of CURB65 risk classes for adverse events (95%CI) | 0.65 (0.61-0.69) | 0.64 (0.59-0.65) | 0.68 (0.57-0.78) | |
AUC of CURB65 risk classes for mortality (95%CI) | 0.73 (0.68-0.75) | 0.72 (0.66-0.77) | 0.74 (0.62-0.86) | |
Initial proADM level (day 0) | ||||
ProADM, median (IQR) (nmol/l) | 1.1 (0.7-1.7) | 1.2 (0.8-1.9) | 0.9 (0.6-1.3) | <0.001 |
ProADM categories | <0.001 | |||
ProADM <0.75 nmol/l, no (%) | 353 (26.0%5) | 194 (21.0%) | 145 (38.3%) | |
ProADM: 0.75 - 1.5 nmol/l, no (%) | 588 (43.3%) | 400 (43.2%) | 166 (43.8%) | |
ProADM >1.5 nmol/l, no (%) | 418 (30.8%) | 331 (35.8%) | 68 (17.9%) | |
AUC of proADM for adverse events (95%CI) | 0.73 (0.69-0.78) | 0.71 (0.67-0.78) | 0.76 (0.66-0.85) | |
AUC of proADM for mortality (95%CI) | 0.79 (0.73-0.85) | 0.76 (0.68-0.83) | 0.88 (0.80-0.94) |